Roche ex­pands its PhI­II pro­gram for Eylea ri­val as long-act­ing da­ta back its block­buster con­tender faricimab

Roche’s Genen­tech has notched an­oth­er suc­cess on its way to chal­leng­ing Re­gen­eron — as well as the oth­er Big Phar­ma con­tender No­var­tis — for the block­buster crown now worn by Eylea.

Re­searchers at the big sub say that their bis­pe­cif­ic Ang-2/VEGF drug faricimab (you once knew it as RG7716) came up with an im­proved pro­file over their fran­chise play­er Lu­cen­tis as a long-act­ing drug for wet AMD. And they scored on long act­ing 16-week da­ta, while Re­gen­eron $REGN and No­var­tis $NVS have been duk­ing it out over the 12-week niche.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.